NCT00834496撤回不适用
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients.
研究概览
简要总结
Sirolimus can be safely switched as early as 90 days after liver transplantation with excellent tolerability and amelioration of the calcineurin inhibitor toxicity that initiated the switch.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (18 years or older) patients undergoing liver transplantation at Thomas Jefferson University Hospital.
- •Diagnosed with at least one of the following CNI side effects 90-180 days post transplantation:
- •CNI renal toxicity. Any liver transplant recipient who has elevated creatinine level (greater than 1.4 mg/dl) and impaired creatinine clearance (MDRD) of 40-60 ml/minute or decreased by 15% compared to baseline in the setting of having a therapeutic CNI level, without suspicion of acute or chronic allograft rejection.
- •Hepatic fibrosis on biopsy. Any patient who has fibrosis seen on liver biopsy with LFT's 2 times the upper normal limit.
- •CNI neurologic toxicity. Any patient who has significant neurological side effects from CNIs. This will include the following: seizures not secondary to an epileptogenic focus or any metabolic derangement; alteration of speech ranging from aphasia to slurred speech; inability to be awake and alert.
- •Post transplant diabetes. Any patient who has developed diabetes after transplant and in whom CNIs are thought to be contributing to poor glycemic control.
- •Signed informed consent at approximately 90 -180 days post transplantation.
排除标准
- •Invasive/surgical therapy within 2 weeks of the 90-180 day post transplantation conversion. (e.g. patients with T-tubes would not be eligible for the study because the T-tube removal will coincide with the conversion date).
- •Open surgical wound at 90-180 days post transplantation.
- •Acute cellular rejection during the first 90-180 days post transplantation.
- •Re-transplants or multiple-organ transplants.
- •Active infection.
- •Malignancy within 3 years prior to liver transplantation (except adequately treated basal cell carcinoma). Patients with HCC prior to transplant will not be excluded.
- •Total cholesterol >300 mg/dl on medical treatment or triglycerides >150 mg/dl at 90-180 days post transplantation.
- •White blood cell count <3,000/mm3 or platelet count <100,000/mm3 at 90-180 days post transplantation.
- •Patients on chemotherapy.
- •Urine protein/creatinine ration > 0.5
结局指标
主要结局
The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients.
时间窗: 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant RecipientsGraft RejectionKidney TransplantRenal Allograft RecipientsRenal TransplantNCT00895583Pfizer254
撤回
4 期
Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant PatientsKidney TransplantationNCT02062892University of Colorado, Denver
终止
4 期
Tacrolimus to Sirolimus Conversion for Delayed Graft FunctionKidney TransplantDelayed Graft FunctionNCT00931255University of Maryland, Baltimore32
进行中（未招募）
不适用
Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients - NDEUCTR2008-006840-20-ITWyeth Pharmaceuticals Inc.300
进行中（未招募）
不适用
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant RecipientsRenal function in kidney transplantMedDRA version: 14.0Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2008-006840-20-DEWyeth, a Pfizer Company256